Clinical Trial

Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2022 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Hepatocellular carcinoma is a highly heterogeneous disease. Treatment strategies for advanced hepatocellular carcinoma are limited. Phosphatidylinositol proteoglycan 3 (GPC3) is a heparan sulfate glycoprotein (HSPG) on the surface of the cell membrane. It is highly expressed in liver cancer tissues, but hardly expressed in normal liver tissues. It is an ideal target for tumor treatment. Investigators aimed to test the safety and efficacy of GPC3 CAR-T cells in patients with advanced hepatocellular carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-11.
Trial Details
NCT Number NCT05620706
Lead Sponsor Shenzhen University General Hospital
Conditions Advanced Hepatocellular Carcinoma
Enrollment 20 participants
Start Date 2022-11-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2022-11-22